For fiscal 2025 (ended Dec 31, 2025), Evogene Ltd reported $3.85M of revenue and -$8.48M of net income.
EVGN revenue was $3.85M for fiscal 2025 (ended Dec 31, 2025), down 30.9% from fiscal 2024. Compound annual growth was +29.9% over 5 years and -10.1% over 10 years. It rose in 4 of the last 10 fiscal years.
EVGN net income was -$8.48M for fiscal 2025 (ended Dec 31, 2025), compared with -$16.48M in fiscal 2024.
EVGN diluted EPS was $1.08 for fiscal 2025 (ended Dec 31, 2025), compared with -$2.90 in fiscal 2024.
EVGN free cash flow was -$13.64M for fiscal 2025 (ended Dec 31, 2025), compared with -$20.33M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $930.0K | $1.04M | $753.0K | $1.75M | $3.38M | $6.54M |
| Cost of revenue | $4.09M | $2.38M | $1.49M | $909.0K | $767.0K | $574.0K | $334.0K | $1.45M | $2.85M | $5.64M |
| Gross profit | -$241.0K | $3.20M | $1.49M | $766.0K | $163.0K | $466.0K | $419.0K | $295.0K | $536.0K | $901.0K |
| Research and development | $7.99M | $12.51M | $16.20M | $20.79M | $21.13M | $17.29M | $15.79M | $14.69M | $16.99M | $16.41M |
| Selling, general and admin | $4.29M | $6.99M | $5.38M | $6.48M | $7.25M | $5.32M | $3.77M | $3.51M | $3.81M | $3.89M |
| Operating income | -$14.03M | -$18.80M | -$22.23M | -$26.94M | -$30.95M | -$24.81M | -$21.17M | -$19.99M | -$21.95M | -$21.09M |
| Interest expense | $1.93M | $3.36M | $928.0K | $3.33M | $1.41M | $2.95M | $555.0K | $2.21M | $1.00M | $891.0K |
| Pre-tax income | -$13.50M | -$14.81M | -$21.95M | -$29.75M | -$30.43M | -$26.17M | -$19.09M | -$20.78M | -$20.83M | -$19.56M |
| Income tax | $1.0K | $9.0K | $19.0K | $90.0K | $13.0K | $32.0K | $24.0K | $30.0K | $11.0K | $36.0K |
| Net income | -$8.48M | -$16.48M | -$23.88M | -$26.64M | -$27.79M | -$23.37M | -$18.11M | -$20.76M | -$20.84M | -$19.59M |
| EPS, basic | $1.08 | -$2.90 | -$5.20 | -$6.44 | -$6.90 | -$8.30 | - | - | - | - |
| EPS, diluted | $1.08 | -$2.90 | -$5.20 | -$6.44 | -$6.90 | -$8.30 | - | - | - | - |
| Diluted shares | 7.9M | 5.7M | 4.6M | 4.1M | 4.0M | 2.8M | 2.6M | 2.6M | 2.6M | 2.5M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.96M | $15.30M | $20.77M | $28.98M | $32.33M | $46.23M | $34.75M | $5.81M | $3.44M | $3.24M |
| Inventory | $210.0K | $1.82M | $76.0K | $566.0K | $92.0K | $0 | - | - | - | - |
| Current assets | $15.63M | $21.59M | $34.47M | $37.75M | $56.89M | $51.82M | $49.03M | $55.49M | $72.79M | $89.49M |
| Total assets | $20.05M | $39.86M | $51.10M | $56.13M | $76.30M | $71.92M | $71.36M | $58.69M | $77.60M | $95.99M |
| Current liabilities | $3.44M | $18.70M | $6.94M | $5.63M | $6.88M | $9.68M | $5.75M | $5.43M | $4.66M | $5.22M |
| Total liabilities | $8.07M | $25.03M | $22.42M | $21.34M | $12.88M | $15.03M | $11.15M | $8.39M | $8.22M | $8.70M |
| Shareholders' equity | -$82.0K | -$1.45M | $28.68M | $34.79M | $63.42M | $56.88M | $60.22M | $50.31M | $69.38M | $87.29M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.50M | -$19.70M | -$21.58M | -$23.68M | -$24.72M | -$19.51M | -$17.67M | -$15.16M | -$15.93M | -$11.69M |
| Capital expenditures | $135.0K | $626.0K | $577.0K | $1.17M | $847.0K | $682.0K | $900.0K | $374.0K | $590.0K | $808.0K |
| Free cash flow | -$13.64M | -$20.33M | -$22.15M | -$24.85M | -$25.56M | -$20.20M | -$18.57M | -$15.54M | -$16.52M | -$12.50M |
| Investing cash flow | $17.74M | $9.62M | -$4.54M | $13.27M | -$20.57M | $9.41M | $37.14M | $17.35M | $15.24M | $4.03M |
| Financing cash flow | -$6.60M | $4.66M | $18.15M | $9.34M | $30.28M | $20.37M | $9.31M | $297.0K | $814.0K | $655.0K |
| Stock-based compensation | $654.0K | $1.24M | $1.11M | $1.19M | $2.61M | $4.10M | $1.58M | $1.73M | $2.24M | $2.94M |
| Depreciation and amortization | $1.14M | $1.38M | $1.30M | $1.51M | $1.30M | $1.79M | $2.40M | $2.02M | $2.15M | $2.28M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -30.9% | 87.0% | 78.0% | 80.1% | -10.6% | 38.1% | -56.9% | -48.3% | -48.3% | -41.2% |
| Gross margin | -6.3% | 57.3% | 50.0% | 45.7% | 17.5% | 44.8% | 55.6% | 16.9% | 15.9% | 13.8% |
| Operating margin | -364.2% | -337.2% | -745.5% | -1608.4% | -3328.3% | -2386.0% | -2810.9% | -1144.2% | -649.1% | -322.5% |
| Net margin | -220.2% | -295.6% | -800.8% | -1590.3% | -2988.5% | -2247.5% | -2405.3% | -1188.2% | -616.3% | -299.6% |
| Free cash flow margin | -353.9% | -364.5% | -742.9% | -1483.5% | -2748.7% | -1941.9% | -2465.6% | -889.2% | -488.6% | -191.1% |
| Return on equity | - | - | -83.2% | -76.6% | -43.8% | -41.1% | -30.1% | -41.3% | -30.0% | -22.4% |
| Return on assets | -42.3% | -41.4% | -46.7% | -47.5% | -36.4% | -32.5% | -25.4% | -35.4% | -26.9% | -20.4% |
| Current ratio | 4.54 | 1.15 | 4.96 | 6.71 | 8.27 | 5.36 | 8.53 | 10.22 | 15.61 | 17.13 |
Source: XBRL data Evogene Ltd files with the SEC, latest filing dated Mar 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Mar 27, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EVGN | $3.85M | -30.9% | -$8.48M | -220.2% | $4.3M |
| NTR | $26.89B | +3.5% | $2.27B | 8.4% | $33.89B |
| CF | $7.94B | +17.9% | $2.18B | 27.5% | $18.07B |
| MOS | $11.90B | +0.0% | -$1.12B | -9.4% | $7.11B |
| ICL | $7.15B | +4.6% | $226.00M | 3.2% | $6.03B |
| SMG | $3.48B | +4.6% | $73.90M | 2.1% | $3.77B |
| UAN | $659.46M | +7.3% | $106.41M | 16.1% | $1.16B |
| CBUS | $4.35M | -10.3% | -$98.19M | -2258.9% | $90.2M |
| AVD | $510.32M | -3.5% | -$54.58M | -10.7% | $28.4M |